Literature DB >> 8024179

[Semi-invasive diffuse pulmonary aspergillosis with antineutrophil cytoplasmic antibodies. 2 cases].

A M Milesi-Lecat1, O Aumaitre, T Deusebis, P Kaufman, A Tridon, M Cambon, J C Marcheix.   

Abstract

We report two cases of semi-invasive pulmonary aspergillosis with a thoracic wall extension in the first case and a parietal vasculitis without Aspergillus invasion in the second. Semi-invasive pulmonary aspergillosis is an identifiable entity. It is characterized by impairment of local pulmonary defense mechanisms and/or a mild systemic immunosuppression as well as a slowly progressive course. Pulmonary symptoms are not specific. The thoracic wall involvement subsequent to a contiguous pulmonary lesion occurs rarely and indicates poor prognosis. CT scan improves diagnosis significantly, confirmed by histology and/or by the biopsy growth of Aspergillus. Itraconazole, tolerated better than amphotericin B, is an efficient treatment though prognosis remains poor (28% of deaths). Detection of anti-neutrophil cytoplasmic antibodies (diffuse cytoplasmic staining) evolving conversely to this disease seems to be associated with infectious vasculitis. These antibodies are found in vasculitis and especially in Wegener's granulomatosis with a high specificity. They have also been described in a few patients with infectious diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8024179

Source DB:  PubMed          Journal:  Ann Med Interne (Paris)        ISSN: 0003-410X


  2 in total

1.  Anticytokeratins are a potential source of false-positive indirect immunofluorescence assays for C-ANCA.

Authors:  J Streicher; B Fabian; K Herkner; H Pointner; P M Bayer
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

Review 2.  Glomerular disease in patients with infectious processes developing antineutrophil cytoplasmic antibodies.

Authors:  Konstantin N Konstantinov; Suzanne N Emil; Marc Barry; Susan Kellie; Antonios H Tzamaloukas
Journal:  ISRN Nephrol       Date:  2013-02-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.